V212 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Herpes Zoster
Conditions
Herpes Zoster
Trial Timeline
Feb 21, 2012 → Feb 26, 2013
NCT ID
NCT01527383About V212 + Placebo
V212 + Placebo is a phase 2 stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT01527383. Target conditions include Herpes Zoster.
What happened to similar drugs?
8 of 20 similar drugs in Herpes Zoster were approved
Approved (8) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01527383 | Phase 2 | Completed |
| NCT01254630 | Phase 3 | Completed |
| NCT00535236 | Phase 1 | Completed |
Competing Products
20 competing products in Herpes Zoster